Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06807463

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease.

The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease.

A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.

The expected trial duration per participant is approximately 86 weeks.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Teva Investigational Site 78139, Fitzroy, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of celiac disease at least 12 months prior to screening
  • On a gluten-free diet for at least 12 months prior to screening
  • Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the trial period
  • Male participants (including vasectomized) with women of child-bearing potential partners (whether pregnant or not) must use condoms and also agree not to donate sperm for the designated period

NOTE - Additional criteria apply, please contact the investigator for more information.

Exclusion criteria

  • A diagnosis or suspicion of refractory celiac disease
  • History of severe celiac-related symptoms following gluten exposure that require acute medical care or intervention of a health care professional
  • Any other gastrointestinal disease or condition that may interfere with the assessment of celiac disease
  • Current or history of malignancy or treatment of malignancy in the last 5 years, excluding treated basal cell carcinoma
  • Pregnant or lactating woman, or plans to become pregnant during the trial; any man who is considering fathering a child or donating sperm during the trial
  • A history of chronic alcohol or substance abuse disorder within the previous 2 years.
  • An active infection(s) requiring treatment with intravenous (iv) anti-infectives (antibiotics, antivirals, antifungals) within 30 days prior to screening or oral anti-infectives (antibiotics, antivirals, antifungals) within 14 days prior to screening
  • Received or intends to receive any live vaccine within 4 weeks or any non-live vaccine 2 weeks prior to investigational medicinal product administration.

NOTE- Additional criteria apply, please contact the investigator for more information

Treatment and study plan

TEV-53408

Drug

Solution for subcutaneous (sc) injection

Placebo

Drug

Solution for subcutaneous (sc) injection

Primary outcomes

  1. Change From Baseline in Villous Atrophy as Measured by Villous Height to Crypt Depth Ratio (Vh:Cd)

    Time frame: Baseline, Week 8

    Vh:Cd is used to assess the severity of celiac disease. It is calculated by dividing the villous height by the crypt depth. A lower ratio indicates more damage.

  2. Number of Participants With at Least One Treatment-Emergent Adverse Event

    Time frame: Up to Week 28

  3. Number of Participants With at Least One Treatment-Emergent Serious Adverse Event

    Time frame: Up to Week 28

  4. Number of Participants With at Least One Protocol-Defined Adverse Event of Special Interest (PDAESI)

    Time frame: Up to Week 28

  5. Number of Participants Who Discontinued From the Study Due to an Adverse Event

    Time frame: Up to Week 28

Secondary outcomes

  1. Change From Baseline in Intraepithelial Lymphocyte (IEL) Density

    Time frame: Baseline, Week 8

  2. Change From Baseline in the VCIEL score

    Time frame: Baseline, Week 8

    VCIEL score is a calculation using the standardized Vh:Cd and standardized IEL. The standardized Vh:Cd is calculated as the difference between the mean Vh:Cd subtracted from each Vh:Cd divided by the Vh:Cd standard deviation. The standardized IEL is calculated as the difference between the mean IEL subtracted from each IEL divided by the IEL standard deviation. VCIEL is the standardized Vh:Cd minus the standardized IEL.

Sponsors and collaborators

Lead sponsor

Teva Branded Pharmaceutical Products R&D LLC

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Feb 4, 2025
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.